Introduction
Malignant transformation requires oncogenic activation and inactivation of tumor suppressor genes, which help cancer cells overriding the normal mechanisms controlling cellular survival and proliferation (1, 2) . These molecular events are caused by genetic alterations (translocations, amplification, mutations) and also by epigenetic modifications (3) . Epigenetic modifications include methylation of DNA cytosine residues and histone modifications and have been shown to be critical in the initiation and progression of cancers (4) . DNA methyltransferase inhibitors and HDAC inhibitors are now being used in the treatment of several hematologic malignancies including MM (5) (6) (7) (8) .
Multiple myeloma (MM) is a plasma cell neoplasm characterized by the accumulation of malignant plasma cells, termed Multiple Myeloma Cells (MMCs) within the bone marrow (BM). Despite the recent introduction of therapies such as Lenalidomide and
Bortezomib, MM remains an almost incurable disease. MM arises through the accumulation of multiple genetic changes that include an aberrant or overexpression of a D-type cyclin gene, cyclin D1 (CCND1) in the case of t(11;14) translocation or gain in 11q13, cyclin D3 (CCND3) in the case of the rare t(6;14) translocation, or cyclin D2 (CCND2) on the background of a translocation involving c-maf (t(14;16)) or MMSET/FGFR3 (t(4;14)) (9, 10) .
Recent studies have shown that epigenetic changes such as DNA methylation play a role by silencing various cancer-related genes in MM. Most of these studies have been performed on limited number of genes using methylation specific PCR (11) (12) (13) (14) (15) (16) (17) (18) .
Among the genes identified with promoter hypermethylation in MM, cyclin-dependent kinase inhibitor 2A (CDKN2A) and transforming growth factor beta receptor 2 (TGFBR2) have been shown to be associated with a poor prognosis in MM patients with discrepant results for CDKN2A (12) . Heller at al. have identified several cancer related genes inactivated through methylation in 3 human myeloma cell lines (HMCLs) and validated the relevance of 10 of these genes in 6 additional HMCLs, premalignant PCs from 24 MGUS patients and MMCs from 111 patients with MM (19) . A methylation of the promoter of the genes coding for secreted protein acidic and rich in cysteine (SPARC) or for Bcl2/adenovirus E1B 19kDa interacting protein 3 (BNIP3) promoters was associated with poor overall survival of MM patients (19) . SOCS3 promoter methylation was found to be associated with extramedullary manifestations, plasma cell leukemia and significant shortened survival in MM patients (20) . More recently, Morgan et al have shown that the transition of normal PC and MGUS stage to MM stage is associated with DNA hypomethylation, but the transition of intramedullary MM stage to plasma cell leukemia or HMCL stage is associated with DNA hypermethylation(21). They described 2 specific subgroups of hyperdiploid MM on the basis of their methylation profile, which had a significantly different overall survival(21).
DNMT inhibitors can be sub-divided into nucleoside analogue and non-nucleoside analogue families. 5-Azacytidine (azacytidine) or 5-Aza-2'-deoxycytidine (decitabine) are both nucleoside analogues with approval for use in myelodysplastic syndrome by Food and Drug Administration. Clinical trials in myeloma combining these demethylating agents with chemotherapy or other agents are underway (8) . An important objective for optimizing these clinical trials will be the identification of biomarkers predictive for sensitivity of MMCs to DNMTi. In the present study, we used gene expression profiling of Multiple Myeloma Cells (MMCs) to build a novel "DNA methylation gene expression score" that makes it possible identification of patients whose MMCs will be targeted by DNMT inhibition.
Materials and methods

Human Myeloma Cell Lines (HMCLs)
XG -1, XG-2, XG-3, XG-4, XG-5, XG-6, XG-7, XG-10, XG-11, XG-12, XG-13, XG-14, XG-16, XG-19, XG-20 and XG-21 human myeloma cell lines were obtained as previously described (22) (23) (24) (25) (26) . JJN3 was kindly provided by Dr Van Riet (Bruxelles, Belgium), JIM3 by Dr MacLennan (Birmingham, UK) and MM1S by Dr S. Rosen (Chicago, USA). AMO-1, LP1, L363, U266, OPM2, and SKMM2 were from DSMZ (Germany) and RPMI8226 from ATTC (USA). All HMCLs derived in our laboratory were cultured in the presence of recombinant IL-6. Gene expression profiling data from HMCLs have been deposited in the ArrayExpress public database under accession numbers E-TABM-937 and E-TABM-1088. The myeloma cell lines were authenticated in our laboratory.
Primary multiple myeloma cells
Bone marrow samples were collected after patients' written informed consent in accordance with the Declaration of Helsinki and institutional research board approval from Heidelberg and Montpellier University hospital. In particular, bone marrow were collected from 206 patients treated with high dose Melphalan (HDM) and autologous stem cell transplantation (ASCT) (27) and this cohort is termed in the following Heidelberg-Montpellier (HM) cohort (Supplementary Table S1 ). The .CEL files and MAS5 files have been deposited in the ArrayExpress public database (E-MTAB-372).
The structural chromosomal aberrations including t(4;14)(p16.3;q32.3) and t(11;14)(q13;q32.3), as well as numerical aberrations including 17p13 and 1q21 gain, were assayed by fluorescence in situ hybridization (iFISH) (28) . We also used Affymetrix data of a cohort of 345 purified MMC from previously untreated patients from the University of Arkansas for Medical Sciences (UAMS, Little Rock, AR). The patients were treated with total therapy 2 including HDM and ASCT (29) and termed in the following UAMS-TT2 cohort. These data are publicly available via the online Gene Expression Omnibus (Gene Expression Profile of Multiple Myeloma, accession number GSE2658). As iFISH data were not available for UAMS-TT2 patients, t (4;14) translocation was evaluated using MMSET spike expression (30) and del17p13 surrogated by TP53 probe set signal (31) . After Ficoll-density gradient centrifugation, plasma cells were purified using anti-CD138 MACS microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany).
Cell culture and treatment for gene expression profiling
The human MM cell lines (HMCLs) XG-5, XG-6, XG-7, XG-20 and LP1 were grown in RPMI 1640 supplemented with 10% fetal bovine serum. Two ng/ml recombinant IL-6 was added to IL-6 dependent HMCLs (XG-5, XG-6, XG-7 and XG-20). Cells (2 x 10 5 /mL) were treated without (control) or with 0.5 μmol/L 5-Aza-2'-deoxycytidine (decitabine, Sigma, St Louis, MO, Figure 1 ) for 7 days as described by Heller et al (19) . At day 3, half the culture medium without (control) or with 0.5 μmol/L decitabine was renewed. This decitabine concentration is the starting one inducing minor decrease in HMCL viability at day 7 of culture (Supplementary Table S2 ). 
Growth assay for myeloma cells
Mononuclear cell culture
Mononuclear cells from tumor samples of 12 patients with MM were cultured for 4 days at 2 x 10 5 cells/ml in RPMI 1640 medium, 10% FCS, 2 ng/ml IL-6, with or without graded concentrations of decitabine. In each culture group, viability and cell counts were assayed and MMCs were stained with an anti-CD138-PE mAb (Immunotech, Marseille, France) as previously described (32) .
Preparation of complementary RNA (cRNA) and microarray hybridization
RNA was extracted using the RNeasy Kit (Qiagen, Hilden, Germany) as previously described (33, 34) . Biotinylated cRNA was amplified with a double in vitro transcription and hybridized to the human U133 2.0 plus GeneChips, according to the manufacturer's instructions (Affymetrix, Santa Clara, CA). Fluorescence intensities were quantified and analyzed using the GECOS software (Affymetrix).
Gene expression profiling and statistical analyses
Gene expression data were normalized with the MAS5 algorithm and analyzed with our bioinformatics platforms -RAGE(35) and Amazonia(36) -or SAM (Significance Analysis of Microarrays) software (37) . The statistical significance of differences in overall survival between groups of patients was calculated by the log-rank test.
Multivariate analysis was performed using the Cox proportional hazards model. 
Results
Modulation of gene expression by decitabine in HMCLs: identification of prognostic genes
Five HMCLs were treated with 0.5 μM of decitabine for 7 days. This was the starting concentration yielding to 10% loss in myeloma cell viability, with the aim to avoid performing gene expression in apoptotic cells (Supplementary Table S2 ) (19) . Using SAM supervised paired analysis, the expression of 48 genes was found to be significantly upregulated and that of 79 genes downregulated by decitabine treatment (FDR < 5%; Supplementary Table S3 and S4). Decitabine-regulated genes are significantly enriched in genes related to "Cancer" and "Cell death" pathways (FDR < 5%; Ingenuity pathway analysis, data not shown). Investigating the expression of these 127 decitabine-regulated genes in primary MMCs of a cohort of 206 newlydiagnosed patients (HM cohort), 22 genes had bad prognostic value and 25 a good one after Benjamini-Hochberg multiple testing correction (Supplementary Table S5 ).
These genes are enriched in genes encoding for interferon signaling pathway (Supplementary Figure 1) . The prognostic information of decitabine-regulated genes was gathered within an DNA methylation score (DM Score), which is the sum of the beta coefficients of the Cox model for each prognostic gene, weighted by ± 1 according to the patient MMC signal above or below the probe set maxstat value as previously described (38) . The value of DM Score in normal, pre-malignant or malignant plasma cells is displayed in Figure 2A . DM Score was similar between normal BMPCs and pre-malignant plasma cells from MGUS patients. MMCs of patients had a significantly higher DM Score than normal BMPCs or plasma cells from MGUS-patients (P < .01), and HMCLs the highest score (P < .001) (Figure 2A myeloma(39), DM Score was significantly higher in the proliferation, t(4;14) and MAF subgroups (P < .001) associated with a poor prognosis (39) and significantly lower in the low bone disease subgroup (P < .001) (39) (Figure 2B ).
Prognostic value of DM score compared to usual prognostic factors
Using patients' HM cohort, DM Score had prognostic value when used as a continuous variable (P ≤ 10 -4 , results not shown), or by splitting patients into two groups using Maxstat R function (38) . A maximum difference in overall survival (OS) was obtained with DM Score = -15.8 splitting patients in a high-risk group of 34.5% patients (DM Score > -15.8) with a 42.1 months median OS and a low risk group of 65.5% patients (DM Score ≤ -15.8) with not reached median survival (Figure 3 ).
Using univariate Cox analysis, DM Score, UAMS-HRS, IFM-score and GPI had prognostic value as well as t(4;14), del17p, β2m, albumin and ISS (Supplementary Table S6 ). When compared two by two, DM Score tested with β2m remained significant. When these parameters were tested together, DM Score, β2m and t(4;14)
kept prognostic value. DM Score was also prognostic for the UAMS-TT2 cohort of 345 patients treated with TT2 therapy (29) . For each patient of UAMS-TT2 cohort, DM Score was computed using parameters defined with patients' HM cohort only. The median OS of patients within high score group (DM Score > -15.8) was 53.7 months and not reached for patients with low DM Score (P = .0008) (Figure 3) . Using Cox univariate analysis, UAMS-HRS, IFM and GPI scores as well as t(4;14) and del17p had prognostic value. Comparing these prognostic factors two by two, DM Score remained significant compared to GPI, t(4;14), and del17p in the UAMS-TT2 cohort (Supplementary Table S6) . When these parameters were tested together, UAMS-HRS, t(4;14) and del17p kept prognostic value. (Table 1) .
In order to determine whether DM Score could predict for the sensitivity of primary MMCs to DNMT inhibitor, we used the maxstat cutoff (DM Score = -15.8) defined in Primary MMCs of patients with a DM Score above maxstat cutoff (-15.8, Figure 2A) exhibited a significant (P < .01) 2.2-fold higher decitabine sensitivity than MMCs with DM Score below maxstat cutoff ( Figure 5 ).
Discussion
In this study, we have identified a gene expression-based DNA methylation score is of major interest to investigate whether this DM Score could predict for patients' response to these inhibitors. Besides a potential interest of DM Score in selecting patients who could benefit from DNMTi therapies, the current study highlights pathways which could be involved in the development of multiple myeloma cells.
Heller at al. have identified several cancer related genes inactivated through methylation in 3 human myeloma cell lines (19) . Among the 127 genes deregulated by decitabine treatment in our HMCL cohort, about one fifth (28 genes 
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